Cyramza (Ramucirumab) Market Report 2026

Cyramza (Ramucirumab) Market Overview

• The Cyramza (Ramucirumab) market growth in the historic period has been driven by approval for gastric and colorectal cancers, rising global cancer burden • Market expansion is supported by increasing incidence of solid tumors, expansion into new oncology indications • Growth Driver: Rising Cancer Incidence Fuels Growth Of Cyramza (Ramucirumab) Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Cyramza (Ramucirumab) Market?

Cyramza (ramucirumab) is a monoclonal antibody used in cancer treatment. It works by targeting and inhibiting the vascular endothelial growth factor receptor 2 (VEGFR-2), which helps prevent tumor blood vessel formation. It is commonly used to treat various cancers, including gastric, colorectal, and lung cancer. The main types of cyramza (ramucirumab) are 100mg/Box, 500mg/Box. 100 mg/box refers to the packaging size of Cyramza (Ramucirumab) where each box contains 100 mg of the drug. It is often used for patients requiring a lower dose of the medication for cancer treatment. The smaller packaging allows for easier distribution and use in various medical settings. It has various applications in advanced gastric cancer, GEJ adenocarcinoma, non-small cell lung carcinoma, metastatic colorectal cancer (MCRC), and hepatocellular carcinoma (HCC) and utilized by end users such as hospitals, cancer treatment centers, ambulatory surgical centers, and research institutes.

What Is The Cyramza (Ramucirumab) Market Growth Forecast?

The cyramza (ramucirumab) market size is expected to see strong growth in the next few years. It will grow to $1.79 million in 2030 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to increasing incidence of solid tumors, expansion into new oncology indications, growth of targeted cancer therapies, rising oncology healthcare spending, improved diagnostic rates. Major trends in the forecast period include growing use of anti angiogenic therapies, expansion across multiple cancer indications, combination use with chemotherapy, rising demand in advanced stage cancers, hospital based oncology administration.

Global Cyramza (Ramucirumab) Market Segmentation

1) By Type: 100mg/Box, 500mg/Box 2) By Application: Advanced Gastric Cancer, GEJ Adenocarcinoma, Non-small Cell Lung Carcinoma, Metastatic Colorectal Cancer (mCRC), Hepatocellular Carcinoma (HCC) 3) By End-User: Hospitals, Cancer Treatment Centers, Ambulatory Surgical Centers, Research Institutes

What Are The Drivers Of The Cyramza (Ramucirumab) Market?

The rising incidence of cancer is expected to propel the growth of the Cyramza (ramucirumab) market going forward. Cancer refers to a group of diseases characterized by uncontrolled cell growth and spread to other parts of the body. The rise in cancer cases can be attributed to factors such as an aging population, lifestyle choices, environmental exposures, improved detection methods, and genetic predispositions. Cyramza (ramucirumab) is used in cancer treatment to target and inhibit the vascular endothelial growth factor receptor 2 (VEGFR-2), helping to prevent tumor blood vessel growth and slow cancer progression. For instance, in August 2024, according to a report published by the Australian Institute of Health and Welfare, an Australia-based national agency for information and statistics on Australia's health and welfare, by 2034, Australia is projected to have approximately 209,000 new cancer diagnoses, a significant increase from the estimated 169,000 cases expected in 2024, reflecting the impact of a growing population and rising cancer rates. Additionally, in 2024, cancer is anticipated to account for about 3 out of every 10 deaths in the country. Therefore, the rising incidence of cancer is driving the growth of the cyramza (ramucirumab) industry. The rise in aging population is expected to drive the growth of the Cyramza (Ramucirumab) market going forward. An aging population refers to a growing proportion of older individuals within a society due to increased life expectancy and declining birth rates. The aging population is increasing due to advancements in healthcare that have extended life expectancy. Cyramza (Ramucirumab) is used by the aging population to help treat advanced cancers by blocking blood vessel growth that fuels tumor progression. For instance, in January 2024, according to the Population Reference Bureau, a US-based non-profit organization, reported that the number of Americans aged 65 and older is expected to rise from 58 million in 2022 to 82 million by 2050, marking a 47% increase. As a result, this age group’s proportion of the total U.S. population will grow from 17% to 23% during this period. Therefore, the rise in aging population is driving the growth of the Cyramza (Ramucirumab) industry. The increasing adoption of personalized medicine is expected to drive the growth of the Cyramza (Ramucirumab) market going forward. Personalized medicine is a medical approach that tailors treatment and prevention strategies to an individual’s unique genetic makeup, lifestyle, and environment rather than using a one-size-fits-all method. Personalized medicine is increasing due to advances in genetic testing that allow treatments to be tailored to individual patient profiles. Cyramza (Ramucirumab) is used as personalized medicine by targeting specific tumor pathways in patients whose cancer shows biomarkers responsive to VEGFR-2 inhibition. For instance, in February 2024, Personalized Medicine Coalition, a US-based non-profit organization, reported that in 2023, the FDA approved 16 new personalized treatments for patients with rare diseases, a significant increase from the six approved in 2022. Therefore, the increasing adoption of personalized medicine is driving the growth of the Cyramza (Ramucirumab) industry.

Key Players In The Global Cyramza (Ramucirumab) Market

Major companies operating in the cyramza (ramucirumab) market are Eli Lilly and Company

Regional Insights

North America was the largest region in the cyramza (ramucirumab) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Cyramza (Ramucirumab) Market?

The cyramza (ramucirumab) market consists of sales of cyramza (ramucirumab) iv infusion and combination therapy formulations. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Cyramza (Ramucirumab) Market Report 2026?

The cyramza (ramucirumab) market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the cyramza (ramucirumab) industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.